Christiane Schuchardt
Robert Koch Allee 9
Bad Berka, TH 99437, Germany
Bad Berka, TH 99437, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma.
Journal: Clinical nuclear medicine
Published: December 03, 2024
Long-term Nephrotoxicity after PRRT: Myth or Reality.
Journal: Theranostics
Published: November 22, 2023
Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles.
Journal: European journal of nuclear medicine and molecular imaging
Published: October 02, 2023
Rapid Tumor Washout of 177 Lu-PSMA Radioligand in Renal Cell Carcinoma.
Journal: Clinical nuclear medicine
Published: June 05, 2023
Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors.
Journal: Clinical nuclear medicine
Published: February 01, 2023
Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation.
Journal: Diagnostics (Basel, Switzerland)
Published: July 18, 2022
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: June 16, 2021
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 28, 2020
First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 16, 2020
First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: February 16, 2020
Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 24, 2019
Last Updated: 09/26/2026